GeneDx Announces Leadership Transition
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118748368/en/

“Everett is one of the most accomplished commercial leaders in our industry, and he is the right person to lead GeneDx into its next phase of growth,” said
“GeneDx has built a remarkable foundation, with unmatched clinical expertise, the world’s largest rare disease genomic dataset and a team that is deeply committed to the families it serves,” said
“Five and a half years ago, I joined GeneDx as CEO to lead its transformation into an independent company, grow the business, and achieve profitability. Together, we’ve delivered on all these commitments. Most of all, I’m proud of what all this work adds up to: more families getting an accurate diagnosis sooner. Part of this journey has been building an exceptional team to lead our next phase of growth, and now is a natural time for me to pass the baton. I’m delighted to welcome Everett and look forward to seeing GeneDx go from strength to strength,” said
GeneDx also reaffirmed its full year 2026 financial guidance, as provided on
About
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s leadership transition, the anticipated contributions of the Company’s new Chief Executive Officer, the Company’s strategy, priorities and future performance and the Company’s full year 2026 financial guidance. Forward-looking statements can generally be identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “strategy,” “future,” “opportunity,” “may,” “should,” “will,” “would,” “will continue” and similar expressions. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied, including, but not limited to: (i) the Company’s ability to manage the leadership transition successfully, including integrating a new Chief Executive Officer and retaining other key personnel; (ii) potential disruption to the Company’s business, operations and relationships with employees, customers, payors and partners resulting from the transition; (iii) the Company’s ability to implement its business plans and identify and realize additional opportunities; (iv) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry; and (v) the size and growth of the market in which the Company operates. The foregoing list is not exhaustive. Additional risks and uncertainties are described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, and other documents the Company files from time to time with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on them, and the Company undertakes no obligation, and does not intend, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261118748368/en/
Investor Relations Contact:
Investors@GeneDx.com
Media Contact:
Press@GeneDx.com
Source: GeneDx